摘要 |
Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salts thereof, wherein: n<SUB>1 </SUB>and n<SUB>2 </SUB>are independently 0-2; Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; B is alkyl or optionally substituted alkenyl; R<SUP>22 </SUP>is -COR<SUP>23 </SUP>or a carboxy, sulfinyl, sulfonyl, sulfonamide or amino acid derivative; R<SUP>23 </SUP>is haloalkyl; alkenyl; haloalkenyl; alkynyl; optionally substituted cycloalkyl; cycloalkyl-alkyl; aryl; arylalkyl; heteroaryl; heterocycloalkyl; or -COOH and/or -SO<SUB>3</SUB>H substituted alkyl; R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>9</SUP>, R<SUP>10 </SUP>and R<SUP>11 </SUP>are as defined in the specification; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.
|